碳离子放疗用于合并间质性肺病的非小细胞肺癌回顾性分析
本回顾性分析纳入29例合并间质性肺病(ILD)且不适合手术或常规放疗的非小细胞肺癌(NSCLC)患者,接受碳离子放疗(CIRT)。3年局部控制率63.3%(I期72.2%),3年生存率46.3%(I期57.2%);4例出现单级症状进展,1例两级进展,2例放射性急性加重。治疗后放射性肺炎进展与肺DVH参数V5、V10及治疗前低血清表面活性蛋白D相关。
要点
- CIRT对合并ILD的NSCLC患者可能是一种低风险的根治性选择。
- 3年局部控制率63.3%,I期达72.2%;3年生存率46.3%,I期57.2%。
- 放射性肺炎进展与肺V5、V10及治疗前低血清表面活性蛋白D相关,应尽量减小低剂量区。
核心结论
- CIRT可能作为合并ILD的NSCLC患者低风险的根治性选择,该人群通常不适合常规治疗。
- DVH分析显示最小化低剂量区对降低严重放射性肺炎风险重要。
研究设计与样本
- 所有患者因ILD不适合根治性手术或常规放疗。
- 评估治疗前后放射性肺炎和症状进展,并分析放射性肺炎与临床因素的关系。
主要发现
- 4例出现单级症状进展(2-3级),1例出现两级进展,2例发生放射性急性加重。
- 3年局部控制率为63.3%(I期疾病为72.2%),3年生存率为46.3%(I期疾病为57.2%)。
- 治疗后放射性肺炎进展与肺DVH参数V5、V10及治疗前低血清表面活性蛋白D相关。
临床怎么用
- 对合并ILD而不适合手术或常规放疗的NSCLC患者,可考虑CIRT作为根治性治疗选项。
- 放疗计划应尽量减小肺低剂量区(V5、V10),以降低严重放射性肺炎风险。
- 治疗前低血清表面活性蛋白D可能提示放射性肺炎进展风险,需结合剂量学因素评估。
局限性
- 本研究为回顾性分析,样本量29例,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung cancer is frequently complicated by interstitial lung disease (ILD). Treatment protocols for lung cancer patients with ILD have not been established; surgery, chemotherapy, and radiotherapy can all cause acute exacerbation of ILD. This study evaluated the toxicity and efficacy of carbon ion radiotherapy (CIRT) in patients with non-small cell lung cancer (NSCLC) and ILD. METHODS: Between June 2004 and November 2014, 29 patients diagnosed with NSCLC and ILD were treated with CIRT. No patient was eligible for curative surgery or conventional radiotherapy secondary to ILD. Owing to prior symptomology, radiation pneumonitis (RP) and symptom progression pre- and post-treatment were evaluated. The relationships between RP and clinical factors were investigated. RESULTS: Twenty-eight men and one woman, aged 62 to 90 years old, were followed for 2.7-77.1 months (median: 22.8 months). Single-grade symptomatic progression (grade 2-3) was observed in 4 patients, while 1 patient experiencedtwo-grade progression. Two patients experienced radiation-induced acute exacerbation. Local control at 3 years was 63.3% (72.2% for stage I disease); survival at 3 years was 46.3% (57.2% for stage I disease). Eighteen patients had died by the time of this writing, 10 of lung cancer progression. Radiation pneumonitis post-treatment progression correlated with dosimetric factors of the lungs (V5, V10) and a low pre-treatment serum surfactant protein-D. CONCLUSIONS: We found that CIRT may be useful as a low-risk, curative option for NSCLC patients with ILD, a population that is typically ineligible for conventional therapy. The DVH analysis showed that minimizing the low-dose region is important for reducing the risk of severe RP. TRIAL REGISTRATION: NIRS-9404 . Registered 1 March 1994.
引用
- Nakajima M, Yamamoto N, Hayashi K, et al. Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis. Radiat Oncol. 2017. PMID: 28865463. doi:10.1186/s13014-017-0881-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。